3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
13
Motor Activity
3
Prostatic Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Behavior
2
Uterine Cervical Neoplasms
1
Smoking Cessation
1
Patient Compliance
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Medication Adherence
1
Lymphedema
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Chronic Pain
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
pembrolizumab
42
Paclitaxel
26
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Nivolumab
16
fludarabine
15
Docetaxel
13
aldesleukin
12
Gemcitabine
11
Fulvestrant
11
veliparib
9
Bevacizumab
9
sargramostim
8
palbociclib
8
durvalumab
8
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
liposomal doxorubicin
7
atezolizumab
7
Surveys and Questionnaires
7
Ipilimumab
7
Blood Specimen Collection
7
niraparib
6
avelumab
6
Taxes
6
Specimen Handling
6
Interleukin-2
6
Fluorouracil
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Motivational Interviewing
×
Breast
×
Clear all
NCT05162846
2026-03-09
MiGHT
University of Michigan Rogel Cancer Center
Phase NA
Completed
831 enrolled